Literature DB >> 15880580

Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas.

Yan Zhang1, Yoshiko Hiraishi, Hua Wang, Ken-saku Sumi, Yasutaka Hayashido, Shigeaki Toratani, Mikio Kan, J Denry Sato, Tetsuji Okamoto.   

Abstract

A G to T mutation at nucleotide position 2128 in the human FGFR3b coding region resulting in a Cys for Gly substitution (G697C) in the tyrosine kinase domain was observed in 62% (44/71) of oral squamous cell carcinomas (OSCC) examined. Immunostained FGFR3b was found in the cytoplasm of prickle cells in normal epithelia, and FGFR3b was localized in the cytoplasm and nucleus in non-FGFR3b mutant OSCC. Overexpressed FGFR3b protein on plasma membranes was noted in OSCC bearing the FGFR3b mutation. Enhanced tyrosine kinase activity of G697CFGFR3b was confirmed. Our results indicate that G697C is an activating mutation causing constitutive ligand-independent FGFR3b signaling. This mutation may be involved in the progression of OSCC and thus the FGFR3b coding sequence may have diagnostic or prognostic value for OSCC. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15880580     DOI: 10.1002/ijc.21145

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Authors:  Marianne E Marshall; Trista K Hinz; Scott A Kono; Katherine R Singleton; Brady Bichon; Kathryn E Ware; Lindsay Marek; Barbara A Frederick; David Raben; Lynn E Heasley
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

Review 2.  Roles of FGFR in oral carcinogenesis.

Authors:  Xiaoyan Xie; Zhiyong Wang; Fangman Chen; Yao Yuan; Jiayi Wang; Rui Liu; Qianming Chen
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

3.  Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells.

Authors:  Norihiro Kotani; Yoshihito Ishiura; Ryusuke Yamashita; Tomoko Ohnishi; Koichi Honke
Journal:  J Biol Chem       Date:  2012-08-29       Impact factor: 5.157

4.  Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.

Authors:  Do-Hee Kim; Yeonui Kwak; Nam Doo Kim; Taebo Sim
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

Review 5.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

Review 6.  Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.

Authors:  Margaret A Knowles
Journal:  World J Urol       Date:  2007-10-03       Impact factor: 4.226

7.  Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip.

Authors:  Annie Chou; Nusi Dekker; Richard C K Jordan
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-04

8.  Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors.

Authors:  Elizabeth K Duperret; Seung Ja Oh; Andrew McNeal; Stephen M Prouty; Todd W Ridky
Journal:  Cell Cycle       Date:  2014-03-12       Impact factor: 4.534

Review 9.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

10.  Mutational Status of FGFR3 in Oral Squamous Cell Carcinoma.

Authors:  P Motahhary; F Baghaie; S Mamishi; B Pourakbari; S Mahmoudi; P Amini Shakib
Journal:  J Dent (Tehran)       Date:  2012-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.